CorMedix sees 1H of 2025 revenue $62M-$70M

Since providing initial guidance, the Company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this new information, CorMedix (CRMD) is increasing its H1 2025 guidance for Net Sales to existing purchasing customers to a revised range of $62 million to $70 million.